• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Randomized Trial Evaluation of Benefits and Risks of Menopausal Hormone Therapy Among Women Aged 50-59.
Abstract The health benefits and risks of menopausal hormone therapy among women aged 50-59 years are examined in the Women's Health Initiative randomized, placebo-controlled trials using long-term follow-up data and a parsimonious statistical model that leverages data from older participants to increase precision. These trials enrolled 27,347 healthy post-menopausal women aged 50-79 at 40 U.S. clinical centers during 1993-1998, including 10,739 post-hysterectomy participants in a trial of conjugated equine estrogens, and 16,608 participants with uterus in the trial of these estrogens plus medroxyprogesterone acet...
Source: Am J Epidemiol - October 7, 2020 Category: Epidemiology Authors: Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JAE Tags: Am J Epidemiol Source Type: research

Why is greater medication adherence associated with better outcomes
Background: To evaluate potential explanations for the association of greater adherence to placebo medication with better outcomes. Methods: The three explanations evaluated were that subjects with greater placebo adherence were 1) more likely to adhere to other medications, 2) had better healthcare behaviors, and 3) had lower risk. The data included more than 800 risk factors from the Women's Health Initiative (WHI), a nationwide study that included women who participated in randomized controlled trials of estrogen plus progestin (n=16,608) or estrogen alone (n=10,739). The median follow-up was 8 years. Linear regression ...
Source: Emerging Themes in Epidemiology - February 2, 2013 Category: Epidemiology Authors: Arthur HartzTao He Source Type: research